indiamed
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
  • News
  • Opinion
  • Interviews
  • IT
  • Finance
  • Strategy
    • Innovation
  • Magazine
facebook x icon x icon linkedin linkedin
all-news

Glenmark to spin off its innovation business into a new company in the US

IMT News Desk
Glenmark Pharmaceuticals, today announced that its Board of Directors has given an in-principle approval to spin off the innovation business into a new company in the US. Setting up of the new company will provide an enhanced focus to the innovation business and help accelerate the pipeline towards commercialization. The new innovation company will be a wholly-owned subsidiary of Glenmark and will be based in the US. It will have an independent board and a new Chief Executive Officer. The other members of the management and the team remain unchanged. “Glenmark has built strong capabilities in the area of innovation in terms of world class infrastructure, talent pool, and technology. We currently have a pipeline of 8 NMEs most of which are first-in-class globally. The cutting edge work that the innovation team has delivered over the years has resulted in numerous achievements most notably among them being the fact that we have out-licensed our novel molecules to big pharmaceutical organizations consistently. With the pipeline at an advanced stage, we believe it’s the right time for the innovation business to be an independent entity and charter its own journey towards becoming a leading biotech organization globally. This change will provide enhanced focus to the business, a better operating ecosystem and additional opportunities to unlock value for the parent company in future," said Glenn Saldanha, chairman and managing director of Glenmark Pharmaceuticals. According to the plan, all innovative molecules in the pipeline, including preclinical assets and technology; the R&D centres in Switzerland, R&D centre at Paramus in the US and R&D centre at Navi Mumbai, India related to the innovation business, and the biologics manufacturing facility in Switzerland along with all employees associated with innovative R&D will be part of the new company. The new company will have over 400 employees as part of this business. The specialty and generics business will continue to be housed in the parent company and will not be part of this new company. The transfer of the assets and employees to the new innovation company is expected to be completed in the next 6 to 9 months.

Recommended

Mykare achieves EBITDA-positive status in elective surgery vertical with 80 per cent revenue growth

Natco Pharma Faces USFDA Scrutiny: 7 Observations at Hyderabad Plant

Nadiad’s DDMM Heart Institute installs real-time cardiac view recognition ultrasound system

India Prepares for 'Disease X' with New National Outbreak Response Team

CitiusTech appoints Navneet Khandelwal as Group CFO

SL Raheja Hospital launches AI-enabled digital PET CT, 3T-MRI and advanced NICU-PICU units

Miltenyi Biotec India, BIRAC sign LoI to advance India’s cell and gene therapy ecosystem

Welcure Secures ₹517 Crore Global Supply Mandate with Thailand’s Fortune Sagar Impex

Indiamedtoday

A premier media platform empowering healthcare professionals with critical business insights, news, and innovations to excel in a rapidly evolving industry.

EMAIL editorial@indiamedtoday.com

EMAIL sales@indiamedtoday.com

quick links

news health it interview opinion strategy magazine privacy policy terms and conditions

subscribe to our newsletter

Stay updated with the latest breakthroughs in Indian healthcare, medical research, and wellness insights.

    follow us

    facebook x icon x icon linkedin linkedin
    Copyright © 2025 INDIAMED TODAY Marketed By Screetract Solutions